Condition
Moderate to Severe Crohn's Disease
Total Trials
3
Recruiting
0
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06450197Phase 2Active Not RecruitingPrimary
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT02148718Phase 4CompletedPrimary
Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease
NCT00630643Phase 1CompletedPrimary
NI-0401 in Active Crohn's Disease
Showing all 3 trials